

## CURRICULUM VITAE

**PHILIP R. MAYER**

### **BUSINESS ADDRESS:**

Wyeth Research  
P.O. Box 42528  
Philadelphia, PA 19101  
(484) 865-5617  
Fax: (484) 865-0058  
Email: mayerp@wyeth.com

### **EDUCATION:**

1971 -1976            B.S. in Pharmacy, University of Kentucky

1976-1981            Ph.D. in Pharmaceutical Sciences, University of Kentucky  
Dissertation: Metabolism of Isosorbide Dinitrate in the Isolated  
Perfused Rabbit Lung  
Major Professor: Dr. \_\_\_\_\_

### **PROFESSIONAL EXPERIENCE:**

1976-Present        Registered Pharmacist in Kentucky

1989-Present        Registered Pharmacist in Texas

1976                  Analytical Assistant, Drug Monitoring Laboratory, University of  
Kentucky Medical Center

1981-1986            Assistant Professor of Pharmacokinetics and Biopharmaceutics,  
Department of Industrial and Physical Pharmacy, School of  
Pharmacy and Pharmacal Sciences, Purdue University

1981-1987            Director, Clinical Pharmacokinetics Laboratory, School of  
Pharmacy and Pharmacal Sciences, Purdue University

1986-1987            Associate Professor of Pharmacokinetics and Biopharmaceutics,  
Department of Industrial and Physical Pharmacy, School of  
Pharmacy and Pharmacal Sciences, Purdue University

1987-Present        Adjunct Associate Professor of Pharmacokinetics, Department of  
Industrial and Physical Pharmacy, School of Pharmacy and  
Pharmacal Sciences, Purdue University

1987-1989            Manager, Pharmacokinetics/Drug Metabolism, Alcon Laboratories

1990-1992	Assistant Director, Pharmacokinetics/Drug Metabolism, Alcon Laboratories
1992-1995	Department Head, Pharmacokinetics Research, Medical Research Division, Lederle Laboratories
1995-1996	Director, Clinical Pharmacokinetics, Clinical Research and Development, Wyeth-Ayerst Research
1997-2000	Senior Director, Clinical Pharmacokinetics, Clinical Research and Development, Wyeth-Ayerst Research
2000-Present	Head, Clinical Pharmacokinetics, Clinical Research and Development, Wyeth Research
2001-Present	Assistant Vice President, Clinical Pharmacology, Clinical Research and Development, Wyeth Research

**PROFESSIONAL ORGANIZATIONS:**

American Association of Pharmaceutical Scientists  
American Society for Clinical Pharmacology and Therapeutics  
American Association of Colleges of Pharmacy  
Rho Chi Pharmacy Honor Society  
Phi Delta Chi Pharmacy Fraternity  
Omicron Delta Kappa Leadership Honor Society

**APPEARS THIS WAY  
ON ORIGINAL**

## **PUBLICATIONS:**

Frederick C. Robinson and Philip R. Mayer: A Graphic Method for Predicting Individual Phenytoin Levels in an Office Practice. *Therapeutic Drug Monitoring*, 4, 225 (1982).

N. J. Patel, D. O. Kildsig, G. S. Banker, P. R. Mayer and M. A. Gonzalez: Paired-Ion High Performance Liquid Chromatographic Assay for Sulfinpyrazone in Plasma. *Journal of Pharmaceutical Sciences*, 71, 1413 (1982).

Roger E. Gordon, Philip R. Mayer and Dane O. Kildsig: Lyophilization-A Means of Increasing Shelf-Life of Phospholipid Bi-Layer Vesicles. *Drug Development and Industrial Pharmacy*, 8, 465 (1982).

Charles Williams, Philip R. Mayer, Mario Gonzalez, Randall J. Erb and Dane O. Kildsig: Comparative Bioavailability of Dipyridamole From Two Tablet Formulations. *Current Therapeutic Research*, 32, 236 (1982).

M. S. El-Ridy, P. R. Mayer, G. E. Peck and D. O. Kildsig: Thermal Analysis of Cimetidine-Caffeine Complexes. *Drug Development and Industrial Pharmacy*, 8, 595 (1982).

Philip R. Mayer, William C. Lubawy, Patrick J. McNamara and Harry B. Kostenbauder: Metabolism of Isosorbide Dinitrate in the Isolated Perfused Rabbit Lung. *Journal of Pharmaceutical Sciences*, 72, 785 (1983).

M. S. El-Ridy, P. R. Mayer, G. E. Peck and D. O. Kildsig: Complex Formation of Cimetidine with Caffeine in Aqueous Solutions. *Drug Development and Industrial Pharmacy*, 9, 453 (1983).

Charles Williams, Philip R. Mayer and Dane O. Kildsig: Dissolution Profiles for Two Tablet Formulations of Dipyridamole. *International Journal of Pharmaceutical Technology and Product Manufacture*, 4, 74 (1983).

Jerry D. Johnson, Philip R. Mayer and Gary E. Isom: Pharmacokinetic Analysis of Potassium Cyanate in Mice Using Whole Blood and Expired Air. *Drug Metabolism and Disposition*, 13, 260 (1985).

Michael E. Brier, Philip R. Mayer, Richard E. Brier, David Visscher, Friedrich C. Luft and George R. Aronoff: Netilmicin Accumulation in Rat Renal Parenchyma. *Antimicrobial Agents and Chemotherapy*, 27, 812 (1985).

Philip R. Mayer and Steven R. Lipp: Hydrochlorothiazide Excretion in Human Breast Milk. *Clinical Pediatrics*, 24, 258 (1985).

T. E. Welty, F. C. Robinson and P. R. Mayer: A Comparison of Phenytoin Dosing Methods in Private Practice Seizure Patients. *Epilepsia*, 27, 76 (1986).

Philip R. Mayer, Charles H. Brown, Rodney A. Carter, Timothy E. Welty, Mark D. Milliken and Nancy K. Eberhard: Intramuscular Tobramycin Pharmacokinetics in Geriatric Patients. *Drug Intelligence and Clinical Pharmacy*, 20, 611 (1986).

Philip R. Mayer: Clinical Pharmacokinetics. 40-Hour Videotape Series, American Association of Colleges of Pharmacy (1987).

Michael E. Brier, George R. Aronoff and Philip R. Mayer: Insulin Metabolism During Acute Renal Failure in the Isolated Perfused Rat Kidney. *American Journal of Physiology*, 253, F884 (1987).

Philip R. Mayer and R. K. Brazzell: Application of Statistical Moment Theory to Pharmacokinetics. *Journal of Clinical Pharmacology*, 28, 481 (1988).

Bruce A. Trela, Gary P. Carlson and Philip R. Mayer: The Effect of Carbon Monoxide on Aminopyrine Metabolism in the Isolated Perfused Rabbit Lung. *Toxicology and Applied Pharmacology*, 96, 442 (1988).

Philip R. Mayer and R. K. Brazzell: What Should Pharmacokinetic Models Do? *Journal of Clinical Pharmacology*, 28, 879 (1988).

J. L. Borowitz, P. R. Mayer, C. A. Rodriguez and M. Antoun: Increased Kidney Glucose Utilization Induced by Cyclosporine: Lack of Relation to Magnesium Excretion. *Fundamental and Applied Toxicology*, 12, 158 (1989).

Bruce A. Trela, Gary P. Carlson and Philip R. Mayer: Effect of Carbon Monoxide on the Cytochrome P-450-Mediated Metabolism of Aniline and p-Nitroanisole in the Isolated Perfused Rabbit Lung. *Journal of Toxicology and Environmental Health*, 27, 331 (1989).

Otto Hockwin, Peter Muller, Jan Krolczyk, Bette A. McCue and Philip R. Mayer: Determination of AL01576 Concentration in Rat Lenses and Plasma by Bioassay for Aldose Reductase Activity Measurements. *Ophthalmic Research*, 21, 285 (1989).

Daniel W. Jasheway, Young H. Park and Philip R. Mayer: A Simple High Performance Liquid Chromatographic Method for the Measurement of 2-Methylsulfonylpyridine in Plasma. *Journal of Analytical Toxicology*, 14, 54 (1990).

Janet Mattern and Philip R. Mayer: Excretion of Fluorescein into Breast Milk. *American Journal of Ophthalmology*, 109, 598 (1990).

Anne L. Coleman, Alan L. Robin, Irvin P. Pollack, Michael J. Rudikoff, Cheryl Enger and Philip R. Mayer: Cardiovascular and Intraocular Pressure Effects and Plasma Concentrations of Apraclonidine Hydrochloride. *Archives of Ophthalmology*, 108, 1264 (1990).

Ganesan Vaidyanathan, Michael Jay, Ranajit K. Bera, Philip R. Mayer and R.K. Brazzell: Ocular Retention of <sup>18</sup>F-Imirestat, A Radiolabeled Aldose Reductase Inhibitor. *Pharmaceutical Research*, 7, 1198 (1990).

R. Kim Brazzell, Philip R. Mayer, Richard Dobbs, Patrick J. McNamara, Renli Teng and John T. Slattery: Dose Dependent Pharmacokinetics of the Aldose Reductase Inhibitor Imirestat in Man. *Pharmaceutical Research*, 3, 112 (1991).

Michael E. Brier, Ronald R. Bowsher, Philip R. Mayer, and David P. Henry: Conversion of p-Tyrosine to p-Tyramine in the Isolated Perfused Rat Kidney: Modulation by Perfusate p-Tyrosine Concentration. *Life Sciences*, 48, 901 (1991).

Jenny Y. Chien, Christopher R. Banfield, Romulus K. Brazzell, Philip R. Mayer, and John T. Slattery: Saturable Tissue Binding and Imirestat Pharmacokinetics in Rats. *Pharmaceutical Research*, 9, 469 (1992).

Mark J. Vocci, Alan L. Robin, John C. Wahl, Phil Mayer, Adrienne Graves, Billie York and Cheryl Enger: Apraclonidine Hydrochloride: An Evaluation of Reformulation and Drop Size. *American Journal of Ophthalmology*, 113, 154 (1992).

Philip R. Mayer, Ronald C. Couch, Mary K. Erickson, C. Bradley Wooldridge and R.K. Brazzell: Topical and Systemic Absorption of Sodium Pyrithione Following Topical Administration to the Nails of the Rhesus Monkey. *Skin Pharmacology*, 5, 154 (1992).

Y.H. Park, R. Barker, B. Griffin, D. Barratt, M. DuPriest, K. Brazzell, B. York, and P. Mayer: Pharmacokinetic and Bioactivity Differences Between Structurally Related Spirohydantoin and Spirosuccinimide Aldose Reductase Inhibitors in the Cynomolgus Monkey. *Xenobiotica*, 22, 543 (1992).

S.D. Hall, M. Hassanzadeh-Khayyat, M.P. Knadler and P.R. Mayer: Pulmonary Inversion of 2-Arylpropionic Acids: Influence of Protein Binding. *Chirality*, 4, 349 (1992).

Philip R. Mayer: Systemic Delivery of Drugs for Ophthalmic Diseases. In "Ophthalmic Drug Delivery Systems", A. Mitra, ed., Marcel Dekker (1993).

Young Han Park, Philip R. Mayer, Ronnie Barker, Mark DuPriest, Brenda W. Griffin, Gary W. Williams and Billie M. York: Comparison of the Pharmacokinetics and Pharmacodynamics of the Aldose Reductase Inhibitors AL03152 (RS), AL03802 (R) and AL03803 (S). *Pharmaceutical Research*, 10, 593 (1993).

Philip R. Mayer: Absorption, Metabolism and Other Factors Which Influence Drug Exposure in Toxicology Studies. *Toxicologic Pathology*, 23, 165 (1995).

Philip R. Mayer: Pharmacokinetic Considerations in Controlled Drug Delivery. In "Controlled Drug Delivery: The Next Generation," K. Park, ed., ACS (1995).

G. Muralidharan, D. Brocklebank and P.R. Mayer: Pharmacokinetics of a Novel Carbapenem Antibiotic, Biapenem, in Healthy Subjects. *Recent Research Developments in Antimicrobial Agents and Chemotherapy*, 1, 333 (1996).

B. Beer, D.E. Clody, R. Mangano, M. Levner, P. Mayer and J.E. Barrett: A Review of the Preclinical Development of Zaleplon, a Novel Non-Benzodiazepine Hypnotic for the Treatment of Insomnia. *CNS Drug Reviews*, 3, 207 (1997).

Mohammed K. Hassanzadeh and Philip R. Mayer: Disposition of Alpha-1-Antitrypsin in the Isolated Rabbit Lung. *Daru*, 7, 29 (1999).

Geraldine M. Ferron, Jeffrey C. Paul, Richard J. Fruncillo, Patrick T. Martin, Lena Yacoub and Philip R. Mayer: Lack of Pharmacokinetic Interaction between Oral Pantoprazole and Cisapride in Healthy Adults. *Journal of Clinical Pharmacology*, 39, 945 (1999).

Simon E. Ball, JoAnn Scatina, John Kao, Richard Fruncillo, Geraldine Ferron, Philip Mayer, Ira Weinryb, Jean Warner and Jeff Hall: Population Distribution and Effects of Drug Metabolism of a Genetic Variant in the 5' Promoter Region of CYP3A4. *Clinical Pharmacology and Therapeutics*, 66, 288 (1999).

Laura C. Strenkoski-Nix, James Ermer, Sheryl DeCleene, William Cevallos and Philip R. Mayer: Pharmacokinetics of Promethazine Hydrochloride Suppositories and Relative Bioavailability Compared to Oral Solution. *American Journal of Health Systems Pharmacy*, 57, 1499 (2000).

Geraldine M. Ferron, William McKeand and Philip R. Mayer: Pharmacodynamic Modeling of Pantoprazole's Irreversible Effect on Gastric Acid Secretion in Humans and Rats. *Journal of Clinical Pharmacology*, 41, 149 (2001).

Geraldine M. Ferron, Richard A. Preston, Robert J. Noveck, Paul Pockros, Philip Mayer, John Getsy, Marybeth Turner, Madelyn Abell and Jeffrey Paul: Pharmacokinetics of Pantoprazole in Patients with Moderate and Severe Hepatic Dysfunction. *Clinical Therapeutics*, 23, 1180 (2001).

Geraldine M. Ferron, Sherry Ku, Madelyn Abell, Mary Unruh, John Getsy, Philip R. Mayer and Jeffrey Paul: Oral Bioavailability of Pantoprazole Suspended in Sodium Bicarbonate Solution. *American Journal of Health-System Pharmacy*, 60, 1324 (2003).

Lauren A. Plante, Geraldine M. Ferron, Mary Unruh and Philip R. Mayer: Excretion of Pantoprazole in Human Breast Milk. *Journal of Reproductive Medicine*, 49, 825 (2004).

Mary Buckwalter, James A. Dowell, Joan Korth-Bradley, Boris Gorovits and Philip R. Mayer: Pharmacokinetics of Gemtuzumab Ozogamicin as a Single-Agent Treatment of Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia. *Journal of Clinical Pharmacology*, 44, 873 (2004).

H. Zhou, M. Buckwalter, J. Boni, P.R. Mayer, D. Raible, J. Wajdula, S. Fatenejad and Marie Sanda: Population-Based Pharmacokinetics of the Soluble TNF $\alpha$  Etanercept: a Clinical Study in 43 Patients with Ankylosing Spondylitis Compared with Post Hoc Data from Patients with Rheumatoid Arthritis. *International Journal of Clinical Pharmacology and Therapeutics*, 42, 267 (2004).

Honghui Zhou, Philip R. Mayer, Joseph Wajdula and Saeed Fatenejad: Unaltered Etanercept Pharmacokinetics With Concurrent Methotrexate in Patients With Rheumatoid Arthritis. *Journal of Clinical Pharmacology*, 44, 1235 (2004).

A.C. Lockhart, R. Bukowski, M.L. Rothenberg, K.K. Wang, W. Cooper, J. Grover, L. Appleman, P.R. Mayer, M. Shapiro and A.X. Zhu: Phase I Trial of Oral MAC-321 in Subjects with Advanced Malignant Solid Tumors. *Cancer Chemotherapy and Pharmacology*, 60, 203 (2007).

Philip Mayer, Susanna Tse, Mary Sendi, Dale Bourg and Dennis Morrison: Steady-State Pharmacokinetics of Premarin in Healthy, Postmenopausal Women (in press, *Journal of Reproductive Medicine*).

David R. Nelson, Manal F. Abdelmalek, Donald G. Raible, Philip R. Mayer and Stephen A. Villano: Early Experience with a Hepatitis-C Virus Polymerase Inhibitor in Phase 1 Clinical Trials (submitted for publication).